Hyeon Hoe Kim
Overview
Explore the profile of Hyeon Hoe Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
279
Citations
2488
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee C, Suh J, Jang D, Jin B, Cho J, Lee M, et al.
Exp Mol Med
. 2024 Jul;
56(8):1807-1815.
PMID: 39085357
TFE3-rearranged renal cell cancer (tRCC) is a rare form of RCC that involves chromosomal translocation of the Xp11.2 TFE3 gene. Despite its early onset and poor prognosis, the molecular mechanisms...
2.
Kwon W, Lee S, Jeong T, Kim H, Lee M
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001482
Antibody-drug conjugates (ADCs) have been a significant advancement in cancer therapy, particularly for urothelial cancer (UC). These innovative treatments, originally developed for hematological malignancies, use target-specific monoclonal antibodies linked to...
3.
Hong J, Han J, Jeong S, Kwak C, Kim H, Jeong C
BMC Genomics
. 2024 Jan;
25(1):46.
PMID: 38200428
Background: The polygenic risk score (PRS) is used to predict the risk of developing common complex diseases or cancers using genetic markers. Although PRS is used in clinical practice to...
4.
Han J, Jeong S, Kim S, Kim G, Yuk H, Ku J, et al.
World J Urol
. 2023 Oct;
41(12):3551-3557.
PMID: 37831155
Purpose: To investigate if increased tubular damage biomarker can predict pathologically upstaged renal cell carcinoma (RCC), which may possess sub-radiologic invasive behavior, leading to surrounding tubular damage. Materials And Methods:...
5.
Kim S, Han J, Jeong S, Yuk H, Ku J, Kwak C, et al.
BMC Urol
. 2023 Mar;
23(1):41.
PMID: 36944962
Background: Clear cell papillary renal cell tumor (CCPRCT) was first reported in 2006 a patient with end stage renal disease. After that it was discovered in the kidney without end...
6.
Kim S, Han J, Jeong S, Yuk H, Jeong C, Kwak C, et al.
Transl Androl Urol
. 2023 Mar;
12(2):168-175.
PMID: 36915877
Background: Previous studies using the Vesical Imaging Reporting and Data System (VI-RADS) to predict muscle-invasive bladder cancer (MIBC) had some limitations. Most studies were performed with transurethral resection of bladder...
7.
Park J, Yuk H, Jeong C, Kwak C, Kim H, Ku J
Investig Clin Urol
. 2022 Nov;
63(6):612-622.
PMID: 36347550
Purpose: This study aimed to compare the functional and oncological outcomes of females who underwent uterus-sparing radical cystectomy (USRC) and standard radical cystectomy (SRC). Materials And Methods: Between February 2009...
8.
Han J, Jeong S, Han S, Yuk H, Ku J, Kwak C, et al.
BMC Cancer
. 2022 Nov;
22(1):1143.
PMID: 36344958
Background: To assess prognostic value of pre-operative ipsilateral split renal function (SRF) on disease-free survival (DFS) and its association with aggressive pathological features in renal cell carcinoma (RCC) patients. METHODS:...
9.
Jeong S, Han J, Jeong C, Kim H, Kwak C, Yuk H, et al.
Front Oncol
. 2022 Aug;
12:858813.
PMID: 35912192
Upper tract urothelial carcinoma (UTUC) occurs in urothelial cells from the kidney and the ureters. Carbohydrate antigen 19-9 (CA 19-9) is a tumor marker for pancreatic and gastrointestinal cancers, and...
10.
Jeong S, Han J, Jeong C, Kim H, Kwak C, Yuk H, et al.
BMC Cancer
. 2022 Jun;
22(1):631.
PMID: 35676678
Background: Non-muscle invasive bladder cancer can be controlled by transurethral resection of bladder (TURB), but suffers from frequent recurrences in 60-70% of cases. Although, recurrence interval after TURB influences treatment...